AC Immune Reports ACI-24 Alzheimer's Trial Safety, Plans Efficacy Boost, Secures $12M Takeda Milestone
ACIU sits 43% above its 52-week low of $1.65.
Summary
AC Immune announced interim safety data for its Alzheimer's drug ACI-24, while also revealing plans to boost its efficacy with an adjuvant and securing a $12 million milestone payment from Takeda.
Key Events · Product Development and Regulatory · ACIU
-
Interim ACI-24 ABATE Trial Data
12-month data from the Phase 1b/2 ABATE trial for ACI-24 in prodromal Alzheimer's disease showed the drug was generally safe and well tolerated with no amyloid-related imaging abnormalities-edema (ARIA-E).
-
Immunogenicity Enhancement Planned
While anti-Abeta antibody responses were detected, the company noted the need to further enhance immunogenicity for more effective plaque removal, leading to the testing of an additional adjuvant in Cohort AD4.
-
Takeda Milestone Payment Received
AC Immune received a $12 million milestone payment from Takeda upon dosing of the first patients in Cohort AD4, reflecting continued partnership commitment and providing non-dilutive funding.
Analysis · ACIU · Life Sciences
AC Immune released interim 12-month data from its Phase 1b/2 ABATE trial for ACI-24 in Alzheimer's disease, demonstrating a favorable safety profile. However, the company indicated a need to enhance immunogenicity for more effective plaque removal, leading to the evaluation of an additional adjuvant in a new cohort. This suggests the current formulation's efficacy may require optimization, potentially impacting the drug's development timeline. Concurrently, AC Immune received a $12 million milestone payment from Takeda, underscoring the partner's ongoing commitment to the program and providing substantial non-dilutive funding.
At the time of this filing, ACIU was trading at $2.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $270.7M. The 52-week trading range was $1.65 to $4.00. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.